Safety Profiles for the HMG-CoA Reductase Inhibitors

This publication has 49 references indexed in Scilit:

• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Cerivastatin
  Drugs, 1998
• Assessing the Observed Relationship between Low Cholesterol and Violence‐related Mortality
  Annals of the New York Academy of Sciences, 1997
• Low Total Serum Cholesterol and Intracerebral Hemorrhagic Stroke: Is the Association Confined to Elderly Men?
  Stroke, 1996
• Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
• Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
• Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors
  Pharmacological Research, 1990
• Serum Cholesterol Levels and Six-Year Mortality from Stroke in 350,977 Men Screened for the Multiple Risk Factor Intervention Trial
  New England Journal of Medicine, 1989
• Myolysis and Acute Renal Failure in a Heart-Transplant Recipient Receiving Lovastatin
  New England Journal of Medicine, 1988
• Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
  New England Journal of Medicine, 1987